FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023340561> ?p ?o ?g. }

• W2023340561 endingPage "902" @default.
• W2023340561 startingPage "893" @default.
• W2023340561 abstract "In Brief Purpose: The purpose of this study was to evaluate the effect of individualized repeated intravitreal injections of ranibizumab (Lucentis, Genentech, South San Francisco, CA) on visual acuity and central foveal thickness (CFT) for branch retinal vein occlusion-induced macular edema. Methods: This study was a prospective interventional case series. Twenty-eight eyes of 28 consecutive patients diagnosed with branch retinal vein occlusion-related macular edema treated with repeated intravitreal injections of ranibizumab (when CFT was >225 μm) were evaluated. Optical coherence tomography and fluorescein angiography were performed monthly. Results: The mean best-corrected distance visual acuity improved from 62.67 Early Treatment of Diabetic Retinopathy Study letters (logarithm of the minimum angle of resolution = 0.74 ± 0.28 [mean ± standard deviation]) at baseline to 76.8 Early Treatment of Diabetic Retinopathy Study letters (logarithm of the minimum angle of resolution = 0.49 ± 0.3; statistically significant, P < 0.001) at the end of the follow-up (9 months). The mean letter gain (including the patients with stable and worse visual acuities) was 14.3 letters (2.9 lines). During the same period, 22 of the 28 eyes (78.6%) showed improved visual acuity, 4 (14.2%) had stable visual acuity, and 2 (7.14%) had worse visual acuity compared with baseline. The mean CFT improved from 349 ± 112 μm at baseline to 229 ± 44 μm (significant, P < 0.001) at the end of follow-up. A mean of six injections was performed during the follow-up period. Our subgroup analysis indicated that patients with worse visual acuity at presentation (≤50 letters in our series) showed greater visual benefit from treatment. “Rebound” macular edema was observed in 5 patients (17.85%) at the 3-month follow-up visit and in none at the 6- and 9-month follow-ups. In 18 of the 28 patients (53.6%), the CFT was <225 μm at the last follow-up visit, and therefore, further treatment was not instituted. No ocular or systemic side effects were noted. Conclusion: Individualized repeated intravitreal injections of ranibizumab showed promising short-term results in visual acuity improvement and decrease in CFT in patients with macular edema associated with branch retinal vein occlusion. Further studies are needed to prove the long-term effect of ranibizumab treatment on patients with branch retinal vein occlusion. Individualized repeated intravitreal injections of ranibizumab showed promising short-term results in visual acuity improvement and decrease in CFT in patients with macular edema associated with branch retinal vein occlusion. Further studies are needed to prove the long-term effect of ranibizumab treatment on patients with branch retinal vein occlusion." @default.
• W2023340561 created "2016-06-24" @default.
• W2023340561 creator A5030893315 @default.
• W2023340561 creator A5032302830 @default.
• W2023340561 creator A5037015545 @default.
• W2023340561 creator A5058613033 @default.
• W2023340561 creator A5067136877 @default.
• W2023340561 creator A5074267070 @default.
• W2023340561 date "2010-06-01" @default.
• W2023340561 modified "2023-09-25" @default.
• W2023340561 title "INTRAVITREAL RANIBIZUMAB (LUCENTIS) FOR BRANCH RETINAL VEIN OCCLUSION-INDUCED MACULAR EDEMA" @default.
• W2023340561 cites W1975265153 @default.
• W2023340561 cites W1977995451 @default.
• W2023340561 cites W1983763042 @default.
• W2023340561 cites W1989523910 @default.
• W2023340561 cites W1989729487 @default.
• W2023340561 cites W2003640321 @default.
• W2023340561 cites W2007190043 @default.
• W2023340561 cites W2007917457 @default.
• W2023340561 cites W2021819922 @default.
• W2023340561 cites W2022621467 @default.
• W2023340561 cites W2026986060 @default.
• W2023340561 cites W2033549802 @default.
• W2023340561 cites W2034440285 @default.
• W2023340561 cites W2038602213 @default.
• W2023340561 cites W2039831816 @default.
• W2023340561 cites W2040410580 @default.
• W2023340561 cites W2043863730 @default.
• W2023340561 cites W2054438872 @default.
• W2023340561 cites W2077389784 @default.
• W2023340561 cites W2078176490 @default.
• W2023340561 cites W2085712747 @default.
• W2023340561 cites W2085947188 @default.
• W2023340561 cites W2124415048 @default.
• W2023340561 cites W2133950656 @default.
• W2023340561 cites W2324588265 @default.
• W2023340561 cites W4246544830 @default.
• W2023340561 cites W4250416245 @default.
• W2023340561 doi "https://doi.org/10.1097/iae.0b013e3181cd4894" @default.
• W2023340561 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20531142" @default.
• W2023340561 hasPublicationYear "2010" @default.
• W2023340561 type Work @default.
• W2023340561 sameAs 2023340561 @default.
• W2023340561 citedByCount "23" @default.
• W2023340561 countsByYear W20233405612012 @default.
• W2023340561 countsByYear W20233405612013 @default.
• W2023340561 countsByYear W20233405612014 @default.
• W2023340561 countsByYear W20233405612015 @default.
• W2023340561 countsByYear W20233405612016 @default.
• W2023340561 countsByYear W20233405612017 @default.
• W2023340561 countsByYear W20233405612018 @default.
• W2023340561 countsByYear W20233405612019 @default.
• W2023340561 countsByYear W20233405612020 @default.
• W2023340561 crossrefType "journal-article" @default.
• W2023340561 hasAuthorship W2023340561A5030893315 @default.
• W2023340561 hasAuthorship W2023340561A5032302830 @default.
• W2023340561 hasAuthorship W2023340561A5037015545 @default.
• W2023340561 hasAuthorship W2023340561A5058613033 @default.
• W2023340561 hasAuthorship W2023340561A5067136877 @default.
• W2023340561 hasAuthorship W2023340561A5074267070 @default.
• W2023340561 hasConcept C118487528 @default.
• W2023340561 hasConcept C134018914 @default.
• W2023340561 hasConcept C141071460 @default.
• W2023340561 hasConcept C2776694085 @default.
• W2023340561 hasConcept C2777802072 @default.
• W2023340561 hasConcept C2778257484 @default.
• W2023340561 hasConcept C2778844676 @default.
• W2023340561 hasConcept C2779829184 @default.
• W2023340561 hasConcept C2780248432 @default.
• W2023340561 hasConcept C2780261187 @default.
• W2023340561 hasConcept C2780347916 @default.
• W2023340561 hasConcept C2780827179 @default.
• W2023340561 hasConcept C2781100027 @default.
• W2023340561 hasConcept C2908732032 @default.
• W2023340561 hasConcept C555293320 @default.
• W2023340561 hasConcept C71924100 @default.
• W2023340561 hasConceptScore W2023340561C118487528 @default.
• W2023340561 hasConceptScore W2023340561C134018914 @default.
• W2023340561 hasConceptScore W2023340561C141071460 @default.
• W2023340561 hasConceptScore W2023340561C2776694085 @default.
• W2023340561 hasConceptScore W2023340561C2777802072 @default.
• W2023340561 hasConceptScore W2023340561C2778257484 @default.
• W2023340561 hasConceptScore W2023340561C2778844676 @default.
• W2023340561 hasConceptScore W2023340561C2779829184 @default.
• W2023340561 hasConceptScore W2023340561C2780248432 @default.
• W2023340561 hasConceptScore W2023340561C2780261187 @default.
• W2023340561 hasConceptScore W2023340561C2780347916 @default.
• W2023340561 hasConceptScore W2023340561C2780827179 @default.
• W2023340561 hasConceptScore W2023340561C2781100027 @default.
• W2023340561 hasConceptScore W2023340561C2908732032 @default.
• W2023340561 hasConceptScore W2023340561C555293320 @default.
• W2023340561 hasConceptScore W2023340561C71924100 @default.
• W2023340561 hasIssue "6" @default.
• W2023340561 hasLocation W20233405611 @default.
• W2023340561 hasLocation W20233405612 @default.
• W2023340561 hasOpenAccess W2023340561 @default.
• W2023340561 hasPrimaryLocation W20233405611 @default.
• W2023340561 hasRelatedWork W1972614420 @default.

• next